강단비 / 지도교수: 조주희

(융합의과학과 석박통합과정)

Gut. 2016 Sep 6. pii: gutjnl-2016-311854. doi: 10.1136/gutjnl-2016-311854. [Epub ahead of print]

Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study.

Sinn DH¹, Kang D², Chang Y³, Ryu S³, Gu S⁴, Kim H⁴, Seong D², Cho SJ⁵, Yi BK⁶, Park HD⁷, Paik SW¹, Song YB⁸, Lazo M⁹, Lima JA⁹, Guallar E⁹, Cho J¹⁰, Gwak GY¹.

 

 

Abstract

 

BACKGROUND AND AIM:

Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome, was associated with subclinical atherosclerosis in many cross-sectional studies, but the prospective association between NAFLD and the progression of atherosclerosis has not been evaluated. This study was conducted to evaluate the association between NAFLD and the progression of coronary atherosclerosis.

 

 

METHODS:

This retrospective cohort study included 4731 adult men and women with no history of cardiovascular disease (CVD), liver disease or cancer at baseline who participated in a repeated regular health screening examination between 2004 and 2013. Fatty liver was diagnosed by ultrasound based on standard criteria, including parenchymal brightness, liver-to-kidney contrast, deep beam attenuation and bright vessel walls. Progression of coronary artery calcium (CAC) scores was measured using multidetector CT scanners.

 

RESULTS:

The average duration of follow-up was 3.9 years. During follow-up, the annual rate of CAC progression in participants with and without NAFLD were 22% (95% CI 20% to 23%) and 17% (16% to 18%), respectively (p<0.001). The multivariable ratio of progression rates comparing participants with NAFLD with those without NAFLD was 1.04 (1.02 to 1.05; p<0.001). The association between NAFLD and CAC progression was similar in most subgroups analysed, including in participants with CAC 0 and in those with CAC >0 at baseline.

 

CONCLUSIONS:

In this large cohort study of adult men and women with no history of CVD, NAFLD was significantly associated with the development of CAC independent of cardiovascular and metabolic risk factors. NAFLD may play a pathophysiological role in atherosclerosis development and may be useful to identify subjects with a higher risk of subclinical disease progression.

 

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

 

KEYWORDS: 

CARDIOVASCULAR DISEASE; FATTY LIVER; FIBROSIS; ULTRASONOGRAPHY

 



(출처_PUBMED) 

조주희교수 연구소개  [프로필 보기] 

 최근 질병의 진단, 치료 예방 또는 의약품 개발에의 응용 등 국내외 다양한 분야에서 임상 연구가 활발하게 이루어 지고 있다. 특히 기초 과학연구를 통하여 밝혀진 개념, 지식이나 손상의 진단, 치료 및 예방 등을 임상에 적용하여 질병의 병인과 발병기전을 밝혀내는 중개임상연구가 급속도로 증가하고 있다. 이러한 중개 연구에 절대적으로 필요한 것이 과학적이고 구체화된 연구 설계인데, 본인의 연구팀에서는 연구자들에게 임상연구설계에 관련된 연구방법론 교육을 제공하고 연구설계와 분석을 도와 주는 동시에 다양한 임상연구에 참여하고 있다. 현재 본인의 연구팀에서는 유방암 환자들의 수술, 항암, 방사선 치료로 인한 피부 변화와 탈모를 조직학적으로 관찰-분석하고 그것이 환자들의 신체, 정신, 사회적 기능과 치료 순응도에 미치는 영향을 조사하는 유방암환자 외모변화 코호트 연구를 진행하고 있다. 그 외에도 신경과와 인지장애의 위험요소 규명연구, 차세대 유전체 사업단과 성격 유전체 연구, 강북코호트 연구 등를 수행하고 있다.